Simone Meneghetti Zatta

Simone Meneghetti Zatta

Auto-generated profile, based on publicly available information

Simone Meneghetti Zatta

Serviço de Oncologia, Hospital Santa Marcelina, São Paulo, SP, Brazil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Sao Paulo Medical Journal
Verified
Journal Article
Open access
PDF file
SKSimone Mayumi Kakubo
Simone Mayumi Kakubo
MMMariel Mendez
Mariel Mendez
JSJuliana Doering Silveira
Juliana Doering Silveira
LMLeonardo Maringolo
Leonardo Maringolo
CNConrado Nitta
Conrado Nitta
TFThiago Fidalgo
Thiago Fidalgo
KEY WORDS: Attention deficit disorder with hyperactivity; Mental disorders; Substance-related disorders; Psychiatry; Comorbidity

19 October 2019 in Current Enzyme Inhibition
Verified
Journal Article
Open access
PDF file
SZSimone Meneghetti Zatta
Simone Meneghetti Zatta
NMNeif Murad
Neif Murad
BABeatriz Alves
Beatriz Alves
LALigia Ajaime Azzalis
Ligia Ajaime Azzalis
VJVirginia Berlanga Campos Junqueira
Virginia Berlanga Campos Junqueira
FFFernando Luiz Affonso Fonseca
Fernando Luiz Affonso Fonseca
Background: The most active agents for the treatment of breast cancer are the anthracyclines whose clinical usefulness is limited by cumulative dose-dependent cardiotoxicity, which results in congestive heart failure among other limiting factors. With all the attempts to minimize chemotherapeutic cardiotoxicity, remote ischemic preconditioning (RIPC) has been considered as a potent endogenous mechanism capable of inhibiting inflammatory responses. Objective: This study aimed to verify if RIPC may be effective as prophylaxis to prevent anthracycline- induced cardiotoxicity in oncological patients. Methods: The preconditioning method was based on four to five-minute cycles of a blood pressure cuff insufflation around the upper arm (either left or right) from 200 mmHg to 250 mmHg, inducing ischemic intervals interspersed with 5 minutes of reperfusion. Results: In this work, echocardiogram results showed a ventricular mass variation that can get worse during chemotherapeutic treatment; however, in patients who had been undergoing RIPC sessions over a period of 6 months, it was observed that this change did not occur. The parameters for troponin T levels were considered; they were higher in patients who were not undergoing RIPC in relation to those who were. When both cases were compared, it was possible to infer that there was a clinically significant improvement for those who went through the procedure. Conclusion: Thus, through the analysis of this study, it is possible to conclude that RIPC is a lowcost, non-invasive procedure which brings cardiac protection for patients undergoing chemotherapy with anthracyclines, providing support in the treatment of cancer.